INSM vs. TAK: Insmed vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Insmed (INSM) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Insmed (INSM) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Insmed (INSM) has a non-negative beta of 0.80.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Takeda Pharmaceutical (TAK) reports 0.56%, ranking against industry peers normally.

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Takeda Pharmaceutical (TAK) reports 0.87%, ranking against industry peers normally.

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Takeda Pharmaceutical (TAK) reports 24.55%, ranking against industry peers normally.

Profitability Metrics

Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Takeda Pharmaceutical (TAK) at -1.66% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

Both Insmed (INSM) at 1.01 and Takeda Pharmaceutical (TAK) at 0.72 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Insmed (INSM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Insmed (INSM) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Takeda Pharmaceutical (TAK) trades at 300.29 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Insmed (INSM) at 16.52 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile relative to book while Insmed (INSM) at 34.55 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics